A depot precursor formulation comprising: a) a controlled-release matrix； b) at least oxygen containing organic solvent； c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.
